Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. (Record no. 25849305)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02131 a2200637 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517085137.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201709s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1476-5594 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1038/onc.2016.41 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Lindblad, O |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20170901 |
| 245 00 - TITLE STATEMENT | |
| Title | Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Oncogene |
| Date of publication, distribution, etc. | 09 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 5119-31 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Animals |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Apoptosis |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Line, Tumor |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Proliferation |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Resistance, Neoplasm |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Leukemia, Myeloid, Acute |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mice |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Morpholines |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mutation |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Niacinamide |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phenylurea Compounds |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phosphatidylinositol 3-Kinases |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phosphoinositide-3 Kinase Inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Protein Kinase Inhibitors |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Signal Transduction |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Sorafenib |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | TOR Serine-Threonine Kinases |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Triazines |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Xenograft Model Antitumor Assays |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | fms-Like Tyrosine Kinase 3 |
| General subdivision | genetics |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cordero, E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Puissant, A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Macaulay, L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ramos, A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kabir, N N |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sun, J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vallon-Christersson, J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Haraldsson, K |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hemann, M T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Borg, Å |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Levander, F |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stegmaier, K |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pietras, K |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rönnstrand, L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kazi, J U |
| 773 0# - HOST ITEM ENTRY | |
| Title | Oncogene |
| Related parts | vol. 35 |
| -- | no. 39 |
| -- | p. 5119-31 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1038/onc.2016.41">https://doi.org/10.1038/onc.2016.41</a> |
| Public note | Available from publisher's website |
No items available.